Containment Drug Delivery Systems Production 
XTalks
JULY 26, 2024
The FDA has issued a warning about dosing errors and subsequent adverse events related to compounded semaglutide injectable products. These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. These errors have led to some patients being hospitalized due to overdoses.
Roots Analysis
FEBRUARY 16, 2022
In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1]
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 20, 2022
The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.
Pharmaceutical Technology
FEBRUARY 3, 2023
While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry. This heightens the risk of cross contamination, requiring effective containment solutions, especially when handling highly potent powders.
Pharmaceutical Technology
FEBRUARY 27, 2023
Antares Pharma overview Antares Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies. It also develops products to reduce the risk of preterm birth in pregnant women.
Pharmaceutical Technology
OCTOBER 26, 2022
It indicates that nanomedicine also has the potential to combat the threat of antibiotic resistance via the use of nanomaterials with intrinsic antibacterial properties, as well as using nanoparticles as effective drug delivery systems for antibacterial agents.
FDA Law Blog
JUNE 13, 2024
As we explained back in March , Teva had initiated Hatch-Waxman pre-launch patent litigation against Amneal for infringement of 5 Orange Book-listed patents reading on the device constituent (a metered dose inhaler) of Teva’s combination product ProAir HFA. b)(1) that drug product patents may be listed if they claim the “drug product.
Expert insights. Personalized for you.
97 
Let's personalize your content